Dirk Müller

Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹In- or ⁶⁸Ga-Labeled Affibody Molecules

Richard P. Baum, Vikas Prasad, Dirk Müller et al. · Journal of Nuclear Medicine · 2010 · 307 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&amp;T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Christiane Schuchardt, Jingjing Zhang, Harshad Kulkarni et al. · Journal of Nuclear Medicine · 2021 · 177 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu DOTA-TATE and ¹⁷⁷ Lu DOTA-NOC

Christiane Wehrmann, Stefan Senftleben, Carolin Zachert et al. · Cancer Biotherapy and Radiopharmaceuticals · 2007 · 175 citations

Medicine, Nuclear Medicine, Oncology +17

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

Jingjing Zhang, Harshad Kulkarni, Aviral Singh et al. · Journal of Nuclear Medicine · 2018 · 122 citations

Medicine, Nuclear Medicine, Oncology +17

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Richard P. Baum, Jingjing Zhang, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2021 · 108 citations · Full text

Medicine, Rehabilitation Medicine, Cardiopulmonary Rehabilitation +16